Navigation Links
DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of,Improved Glycemic Control and Significant Reductions of,LDL-Cholesterol and C-Reactive Protein

Top Line Data for the Treatment of Type 2 Diabetes Presented at the 67th Annual Scientific Sessions of American Diabetes Association

SAN FRANCISCO, June 25, 2007 /PRNewswire/ -- DiObex, Inc., a privately-held biopharmaceutical company focused on the development of therapeutics to treat metabolic diseases, today announced the presentation of top line data of its phase 2a study of DIO-902, a first-in-category Cortisol Synthesis Inhibitor for the treatment of type 2 diabetes.

Results of the two week placebo-controlled, dose-ranging study demonstrated that in patients treated with DIO-902 there was a trend toward improved glycemic control as measured by HbA1c, fructosamine and fasting blood glucose, as well as significant dose-dependent reductions in total and LDL- cholesterol. Mean levels of C-reactive protein (a marker of cardiovascular inflammation) were also significantly reduced in a dose-dependent fashion. Besides glycemic control, the additional benefits provided by DIO-902 may allow type 2 diabetes patients to manage their disease with fewer medications.

The data was presented at the 67th Annual Scientific Sessions of the American Diabetes Association (ADA) in Chicago, IL by Sherwin Schwartz, MD, lead investigator from the Diabetes and Glandular Disease Clinic of San Antonio, Texas. In his oral presentation, Dr. Schwartz detailed the results of the recently completed multi-center, randomized, placebo-controlled trial of DIO-902 in patients with type 2 diabetes.

"DIO-902 was well tolerated and we saw early signals of improvements in glycemic control," said Dr. Schwartz. "In addition, DIO-902 also showed early indications of potential to reduce the risk of heart disease through the significant reduction of LDL-cholesterol by as much as 46 percent at the highest dose studied. The prospect of a single therapeutic which has the potential to address multiple co-morbidities is very exciting."<
'"/>




Page: 1 2 3

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
11. Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey
Post Your Comments:
(Date:9/3/2015)... India , September 3, 2015 ... Metallic compounds, Organosulfurs, Organic acids, Phenolics, and Others) and ... & beverage, Paints & coatings, and Others) - Global ... and segments the Biocides Market with an analysis and ... as value. Browse   88 tables ...
(Date:9/2/2015)... Balloon angioplasty is a minimally invasive ... report is on global angioplasty balloons studies the ... report comprises an elaborate executive summary, which includes ... various segments and sub-segments included in the study. ... data analysis of the global angioplasty balloons market ...
(Date:9/2/2015)... , Sept. 2, 2015 About ... artificial implants used to replace, augment, or repair ... a wide range of applications including cosmetic, spinal, ... are made of different materials such as polymers, ... the global implantable medical devices market to grow ...
Breaking Medicine Technology:Biocides Market Worth 10.6 Billion USD by 2020 2Biocides Market Worth 10.6 Billion USD by 2020 3Biocides Market Worth 10.6 Billion USD by 2020 4Biocides Market Worth 10.6 Billion USD by 2020 5Angioplasty Balloons Market: : Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 2Angioplasty Balloons Market: : Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3Global Implantable Medical Devices Market 2015-2019 2
... Corporation (NYSE: GPX ), announced today that ... with and into its wholly-owned subsidiary, General ... Physics, which is the sole operating subsidiary of GP ... be renamed GP Strategies Corporation when the merger becomes ...
... 15, 2011  MedAssurant, Inc., a leading provider ... Healthcare Partners, IPA (HCPIPA), one of the ... the Northeast, has selected MedAssurant,s Prospective Advantage® ... proactively identify gaps in care and quality ...
Cached Medicine Technology:GP Strategies Shareholders Approve Elimination of Holding Company Structure and Renaming of General Physics Corporation 2GP Strategies Shareholders Approve Elimination of Holding Company Structure and Renaming of General Physics Corporation 3Healthcare Partners, IPA, Implements MedAssurant's Innovative, Data-Driven Solutions 2Healthcare Partners, IPA, Implements MedAssurant's Innovative, Data-Driven Solutions 3
(Date:9/2/2015)... ... 2015 , ... One can hardly argue against the fact that more and ... personal computers. These devices are being used as GPS, to make purchases, and yes, ... apps, STD positive singles can now join the prestigious social ranks of e-dating. ...
(Date:9/2/2015)... ... September 03, 2015 , ... ... determine who among America’s policymakers, public servants, activists, corporate executives, entrepreneurs, health care ... care. This year, that process led the magazine to tap the National League ...
(Date:9/2/2015)... ... September 02, 2015 , ... Chris Harrison of Harrison’s ... “It was a simple decision, really,” says Chris. “We have a lot of repeat ... the brands that work best for them—so we’ve given them the convenience of ordering ...
(Date:9/2/2015)... ... September 02, 2015 , ... Healthegy, a leading ... two leaders who will deliver keynote presentations at the upcoming Digital Healthcare Innovation ... Hotel in Boston. , Larry Renfro, CEO of Optum, will deliver the morning ...
(Date:9/2/2015)... CA (PRWEB) , ... September 02, 2015 , ... Based ... expand their fleet of truly superb luxury vehicles based on which of the latest ... to announce the latest step forward in pursuit of this goal: a 2015 ...
Breaking Medicine News(10 mins):Health News:Herpes-datingsites.com Recently Added Reviews of 5 STD Dating Apps for STD Positive Singles 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:Harrison's Comfort Footwear Announces Expansion with New CHarrison Online Store 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:Luxury Line Auto Rental Announces Addition of the Rolls Royce Wraith to their Luxury Fleet 2
... , ... ... ... ...
... ... ... ... ...
... be key, and an existing drug might help, scientists ... scientists say they,ve learned new details about molecular mechanisms ... lead to new treatments for alcoholism. , The University ... access to alcohol or sugar for nearly two months, ...
... seem to be making progress against these viruses, research ... of vaccination and prevention efforts may have the hepatitis ... from the U.S. Centers for Disease Control and Prevention. ... to various hepatitis strains. Antibodies are a kind of ...
... University have developed a new analytical method that opens ... information, with applications in fields as diverse as the ... we address here is this: When faced with a ... pieces of that information are relevant for solving a ...
... get life-threatening diseases under control, patients in the intensive ... same time. Even for experts, it is difficult to ... and interactions. The team headed by Dr. Thilo Bertsche, ... Heidelberg University Hospital, has now shown that physicians can ...
Cached Medicine News:Health News:The NASCAR Foundation Announces 'The Big Five' Projects for NASCAR Day 2Health News:The NASCAR Foundation Announces 'The Big Five' Projects for NASCAR Day 3Health News:The NASCAR Foundation Announces 'The Big Five' Projects for NASCAR Day 4Health News:Visionworks(R) Provides Eye Care For Pittsburgh's Smiling Irish Eyes 2Health News:Visionworks(R) Provides Eye Care For Pittsburgh's Smiling Irish Eyes 3Health News:Alcoholics' Relapses Better Understood 2Health News:Vaccination, Prevention Is Beating Back Hepatitis 2Health News:Research streamlines data processing to solve problems more efficiently 2Health News:Risk for patients in the intensive care unit clearly reduced 2
... is an economically priced 4-channel data ... research use in the fields of ... biology, zoology, biochemistry and biomedical engineering. ... signal conditioners and transducers. Two Pod ...
Near PT test card/Tumbling E, tumbling hands 5 1/2" X 8"....
Tumbling E/20' distance chart 22-1/2" X 11" 20/200 to 20/10....
... charts contain 5 pages of various contrast levels ... size is 9.5M. Contrast levels are 25%, 10%, ... be used at several different distances. These two ... offers a different set of symbols to ...
Medicine Products: